Pharnext is analyzing clinical trial data that could support applications to approve PXT3003, its therapy candidate for people…
Articles by Patricia Inácio, PhD
The country music community is coming together for “A Night at the Opry,” one of many events lined up…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Vanda Pharmaceuticals’ VCA-894A for treating…
Neuropathic pain due to damage or impairment in the nervous system is common with Charcot-Marie-Tooth disease and linked with…
A 52-year-old man was diagnosed with Charcot-Marie-Tooth disease type 1 subtype A (CMT1A), after presenting a history of muscle…
The CMT Research Foundation (CMTRF) is joining forces with Augustine Therapeutics to accelerate research into a small…
A new report describes the case of a 63-year-old man diagnosed with an atypical, severe form of Charcot-Marie-Tooth disease…
Moderate to severe anxiety, depression, and general distress affect up to 25% of people with Charcot-Marie-Tooth disease (CMT), according…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases…
The CMT Research Foundation has granted over $500,000 to help develop a gene therapy for Charcot-Marie-Tooth disease type…